Peapack Gladstone Financial Corp decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 21.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 45,945 shares of the medical instruments supplier’s stock after selling 12,290 shares during the period. Peapack Gladstone Financial Corp’s holdings in Becton, Dickinson and Company were worth $8,916,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company during the third quarter valued at approximately $25,000. Steph & Co. increased its stake in shares of Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares in the last quarter. Cornerstone Planning Group LLC increased its stake in shares of Becton, Dickinson and Company by 463.3% during the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 139 shares in the last quarter. Accredited Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 70 shares during the last quarter. Finally, WPG Advisers LLC grew its holdings in shares of Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 61 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.
Analyst Ratings Changes
A number of research firms have recently commented on BDX. Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Evercore increased their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Citigroup cut their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Barclays increased their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $183.64.
Becton, Dickinson and Company Trading Down 1.2%
Shares of BDX stock opened at $145.35 on Tuesday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average is $151.40 and its 200 day moving average is $176.68. The stock has a market capitalization of $40.05 billion, a P/E ratio of 36.80, a P/E/G ratio of 10.42 and a beta of 0.22.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
